FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

Published Date: 23 Feb 2026

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Race, Geography Linked to Gaps in Prostate Cancer Care

2.

Sports for girls are frequently abandoned due to uniform issues.

3.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

4.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

5.

Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot